Scholar Rock Holding Corporation
SRRK
Rank in Stocks
#3481
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Share Price
$40.54
Last synced: 2026-10-19
Market Cap
$4.94B
Change (1 day)
1.59%
Change (1 year)
45.19%
Country
US
Trade Scholar Rock Holding Corporation (SRRK)
Category
Healthcare
P/E ratio for Scholar Rock Holding Corporation (SRRK)
P/E ratio as of October 2026 TTM: -11.96
According to Scholar Rock Holding Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -11.96. At the end of 2023 the company had a P/E ratio of -8.62.
P/E ratio history for Scholar Rock Holding Corporation from 2016 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -11.96 | -31.71% |
| 2024 | -17.52 | 103.34% |
| 2023 | -8.62 | 110.25% |
| 2022 | -4.10 | -40.77% |
| 2021 | -6.92 | -60.57% |
| 2020 | -17.55 | 140.29% |
| 2019 | -7.30 | 0.18% |
| 2018 | -7.29 | -34.34% |
| 2017 | -11.10 | -35.16% |
| 2016 | -17.12 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -340.58% |
US
|
|
| -28.36 | 137.04% |
US
|
|
| -24.57 | 105.35% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -353.52% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.